Concomitant use of gastrointestinal prescribed medication was greater in the stent group ( BS 5.1 , ED 2.0 prescriptions ; P < 0.001 ) , as were related adverse events ( BS 1.4 , ED 0.0 events ; P = 0.024 ) .